Skip to main content

SK-N-SH Cell Line

The SK-N-SH cell line was established in 1970 from the bone marrow metastasis of a 4-year-old female with neuroblastoma. SK-N-SH cells exhibit an epithelial morphology and adherent cultural properties. SK-N-SH is capable of differentiating and exhibiting neurite outgrowths. This hyperdiploid cell line has a modal chromosome number of 47 and is genetically female with two X chromosomes. SK-N-SH cells express blood type A and Rh+ , as well as produce high levels of dopamine-beta-hydroxylase.

Pediatric brain cancer is one of the leading causes of cancer-related deaths in children under 20 years old, and neuroblastoma cell lines like SK-N-SH are valuable tools in preclinical research that allow scientists to develop new drugs and treatments. A pre-optimized SK-N-SH transfection reagent to transfect SK-N-SH cells and conduct brain cancer research is commercially available from Altogen Biosystems. SK-N-SH cells can also be used to study neural pathways.

Past studies have shown that reducing miR-21 in breast, gastric, and colon cancer cell lines negatively affects tumor growth; however, the effects of reducing miR-21 in neuroblastoma cell lines had not yet been investigated. In a 2017 Oncology Letters study written by Wang et al., researchers use transfection methods to investigate how reducing microRNA (miR-21) affects SK-N-SH neuroblastoma cells. MicroRNA (miR-21) is an oncogenic version of miRNA, which is a short non-coding RNA that plays an important role in cell migration, proliferation, and differentiation. Researchers transfected an miR-21 inhibitor oligonucleotide into an SK-N-SH cell line. Quantitative polymerase chain reaction analysis and Western blotting analysis were used to detect the expression of miR-21 and examine the levels of PTEN, PDCD4 and caspase-3 proteins. Results revealed that the miR-21 inhibitor inhibited SK-N-SH cell proliferation and induced apoptosis. The miR-21 inhibitor also led to a significant increase of proteins PTEN and PDCD4 in SK-N-SH cells. Moreover, a control group with SK-N-SH cells that were not transfected with the miR-21 inhibitor showed an increase in caspase-3 protein expression. These findings suggest that miR-21 can serve as a novel therapeutic target in the treatment of neuroblastoma patients.

Comments

Post a Comment

Popular posts from this blog

SK-N-SH Transfection Reagent (Neuroblastoma Cells, HTB-11)

The SK-N-SH cell line was isolated in 1970 from the brain tissue extracted from a 4-year-old female patient suffering from a neuroblastoma. These cells are ideal as transfection hosts because they are known to express high levels of dopamine-beta-hydroxylase and having a higher doubling time. SK-N-SH are used in biomedical research for certain types of brain cancer. Altogen Biosystems  manufactures and prepares a SK-N-SH transfection reagent that is cationic lipid based with a high transfection efficacy. This reagent is proven to establish stable cell lines for reliable yields.   Transfection Reagent for SK-N-SH Cells (Neuroblastoma Cells, HTB-11)
Read more

Brain Cancer Xenografts and Custom Research from Altogen

Altogen Biosystems is a quality producer and custom research organization for genetic research. Custom biological products and other experiments include siRNA screening, optimization of preclinical research, stable transfection of cells, RNAi testing and more. Dedicated to benefiting researchers with state-of-the-art and specialized services, Altogen Biosystems aims to further modern clinical discoveries. Visit Altogen Biosystems’ catalog for custom brain cancer xenograft models .
Post a Comment
Read more